IUI1:F:F-Intuitive Surgical Inc (EUR)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 429.2

Change

0.00 (0.00)%

Market Cap

USD 152.52B

Volume

119.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESL:F EssilorLuxottica Société ano..

N/A

USD 97.14B
ESLC:F ESSILORLUXOTTICA 1/2/O.N.

N/A

USD 96.96B
BOX:F Becton Dickinson and Company

N/A

USD 60.55B
HYB:F HOYA Corporation

N/A

USD 44.70B
HYB0:F HOYA CORP. ADR/ 1 O.N.

N/A

USD 43.06B
RMEA:F Resmed Inc DRC

N/A

USD 32.25B
RME:F ResMed Inc

N/A

USD 31.88B
CBH:F COLOPLAST SP.ADR 1/10 DK1

N/A

USD 26.54B
CBHD:F Coloplast A/S

N/A

USD 26.34B
QS50:F STRAUM.HLD.UNSP.ADR/1/10

N/A

USD 23.41B

ETFs Containing IUI1:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -53.39% 18% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -53.39% 18% F 11% F
Trailing 12 Months  
Capital Gain -48.15% 16% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.15% 16% F 15% F
Trailing 5 Years  
Capital Gain -70.92% 11% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -70.92% 11% F 11% F
Average Annual (5 Year Horizon)  
Capital Gain 3.84% N/A N/A 55% F
Dividend Return 3.84% N/A N/A 49% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 45.21% N/A N/A 23% F
Risk Adjusted Return 8.49% N/A N/A 43% F
Market Capitalization 152.52B 100% F 99% N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.